The new CEO of Sanofi, the French drug giant, believes that its drug Dupixent, for the treatment of severe rashes and asthma, could surpass $10 billion in annual sales.
Paul Hudson, who became CEO in September, said Monday that growing sales of Dupixent, which is sold with the U.S. biotech Regeneron, would be Sanofi’s top priority. It “has the chance to be one of the most successful medicines in the history of the industry, built on the back of patients with huge unmet need who are living horribly debilitated lives, who can reach, in many cases, normal lives,” Hudson said.
About the Author Reprints
